Skip to main content
IBRX
NASDAQ Life Sciences

ImmunityBio Reports Record Q1 Revenue and Strong Cash Position, Driven by ANKTIVA Growth

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$6.94
Mkt Cap
$7.176B
52W Low
$1.83
52W High
$12.43
52W Position info
279% above low
Off High info
44% below high
Rel. Volume info
0.4× avg
Market data snapshot near publication time

IBRX has more than doubled off its 52-week low of $1.83.

Summary

ImmunityBio announced strong preliminary Q1 2026 financial results, including record net product revenue of $44.2 million and a healthy cash balance of $380.9 million, driven by ANKTIVA's continued commercial success.


Key Events · Earnings and Guidance · IBRX

  • Record Q1 2026 Net Product Revenue

    Reported preliminary net product revenue of $44.2 million for Q1 2026, representing a 168% increase year-over-year compared to Q1 2025 and a 15% sequential increase from Q4 2025.

  • Strong Cash Position

    Ended Q1 2026 with an estimated $380.9 million in cash, cash equivalents, and marketable securities.

  • ANKTIVA Commercial Momentum

    ANKTIVA unit sales volume increased by 168% year-over-year in Q1 2026, with the product now approved or authorized in 5 regulatory jurisdictions, encompassing approximately 34 countries.

  • Positive Clinical & Regulatory Updates

    NCCN Clinical Practice Guidelines were updated in March 2026 to include ANKTIVA plus BCG for BCG-unresponsive NMIBC with papillary-only disease. Additionally, the pivotal BCG-naïve NMIBC CIS trial (QUILT-2.005) is fully enrolled, with a supplemental BLA submission on track for 2026.


Analysis · IBRX · Life Sciences

ImmunityBio's preliminary Q1 2026 results demonstrate robust commercial execution for ANKTIVA, with significant year-over-year and sequential revenue growth. The substantial cash balance provides financial flexibility, while positive clinical and regulatory updates further strengthen the company's long-term outlook. This official filing confirms the strong preliminary results previously reported by news outlets today. Investors should monitor the final Q1 2026 10-Q for confirmation of these preliminary figures and continued ANKTIVA adoption.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IBRX was trading at $6.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.2B. The 52-week trading range was $1.83 to $12.43. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IBRX - Latest Insights

IBRX
Nov 09, 2026, 7:52 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.59
Real-time Price: $6.08 info
Change: -$1.51 (-20%) info
Market Cap: $6.404B info
IBRX
Nov 09, 2026, 7:39 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.09
Real-time Price: $6.08 info
Change: -$2.01 (-25%) info
Market Cap: $6.404B info
IBRX
Nov 09, 2026, 7:30 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $8.84
Real-time Price: $6.08 info
Change: -$2.76 (-31%) info
Market Cap: $6.404B info
IBRX
Nov 09, 2026, 6:30 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $8.76
Real-time Price: $6.08 info
Change: -$2.68 (-31%) info
Market Cap: $6.404B info
IBRX
Oct 16, 2026, 11:49 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $9.42
Real-time Price: $6.08 info
Change: -$3.34 (-35%) info
Market Cap: $6.404B info